Current Report Filing (8-k)
August 07 2020 - 07:34AM
Edgar (US Regulatory)
FALSE0001447028701 Veterans
CircleWarminsterPennsylvania00014470282020-08-062020-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event
reported): August 7, 2020
Arbutus Biopharma Corporation
(Exact name of registrant as specified in charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
British Columbia, Canada |
|
001-34949 |
|
98-0597776 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
|
|
|
|
|
|
|
701 Veterans Circle
Warminster, Pennsylvania
|
|
18974 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(267) 469-0914
Registrant’s telephone number, including area code
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
|
|
|
|
|
|
|
☐ |
Written communication pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement communication pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement communication pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Shares, without par value |
|
ABUS |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the
Exchange Act. o
Item 2.02. Results of Operations and Financial
Condition.
On August 7, 2020, Arbutus Biopharma Corporation (the
“Company”) issued a press release announcing its financial results
for the quarter ended June 30, 2020 and certain other
information. A copy of the press release is furnished as Exhibit
99.1 hereto.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
|
|
|
|
|
|
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
|
|
104 |
|
Cover page interactive data file (formatted as inline
XBRL). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
Arbutus Biopharma Corporation |
|
|
|
|
|
|
Date: August 7, 2020 |
By: |
/s/ David C. Hastings |
|
|
Name: |
David C. Hastings |
|
|
Title: |
Chief Financial Officer |
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Dec 2020 to Jan 2021
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Jan 2020 to Jan 2021
